Louisiana Gains New Immunotherapy for Airway Papillomatosis

Patients with recurrent respiratory papillomatosis who need frequent surgery now have a new FDA-approved treatment option in the state.

Updated on Nov. 7, 2026 in Health

Bold flat-color vector illustration of a single clear glass vial with amber liquid on a teal surface, evoking a new treatment option for a rare airway condition.
FMOL Health has begun administering Papzimeos, the first FDA-approved immunotherapy for recurrent respiratory papillomatosis, to Louisiana patients, starting in mid-September 2026. AI Illustration. Upload story photo >

Live Poll

Do you trust local doctors to offer the newest treatments for rare diseases?

FMOL Health has begun administering Papzimeos, a newly available, FDA-approved immunotherapy for recurrent respiratory papillomatosis (RRP), and is the first provider in Louisiana to offer it. Treatment began in mid-September 2026, and the therapy is aimed at patients with the rare, chronic condition who need frequent procedures to manage it.

Why it matters

RRP is caused by certain strains of HPV and often requires repeated surgery or chemotherapy to clear growths from the airway, so a treatment that can reduce that burden matters for Louisiana patients who currently face frequent interventions. Papzimeos is positioned as the next step when the Gardasil vaccine does not work, giving affected patients in the state a new option.

The FDA trial found that over half of patients never needed surgery again after treatment with Papzimeos. Its long-term durability beyond the trial period is not described in the reporting.

The players

FMOL Health

A Louisiana health system that has become the first in the state to administer Papzimeos to patients with recurrent respiratory papillomatosis.

Our Lady of the Lake's Voice Center

The clinic where Dr. Adkins treats patients with voice and airway conditions, including RRP.

The details

Papzimeos trains a patient's immune system to recognize and destroy HPV-infected cells. The treatment is given as four shots over 12 weeks, and patients often undergo surgery first to clear the airway before the immunotherapy series begins. Eligibility requires at least three surgeries or procedures a year.

Timeline

  1. Mid-September 2026: FMOL Health began administering Papzimeos shots.

  2. November 7, 2026: FMOL Health's first-in-Louisiana status was announced.

Health Landscape

Gardasil is the established HPV vaccine that prevents infection, but it does not treat existing HPV-driven disease such as RRP. Papzimeos fills that treatment gap as an immunotherapy for patients whose disease persists despite prior vaccination efforts.

If you have recurrent airway growths or have been told you need repeated procedures for RRP, it is worth asking your physician whether an immunotherapy like Papzimeos may be appropriate for your situation. Patients who need frequent surgeries should also discuss the care setting, the four-shot series, and whether pre-treatment surgery to clear the airway is part of the plan.

The takeaway

Papzimeos gives Louisiana patients with recurrent respiratory papillomatosis a new immunotherapy option where repeated surgery has been the main tool. If you have RRP or a family member does, ask your physician whether referral to a specialist treating airway conditions is appropriate.

Further reading

For broader context on HPV-related disease and treatment in the state, explore more Cancer coverage on We are Healthy.

Source note: This article includes information reported by Wafb.

Live Poll

Do you trust local doctors to offer the newest treatments for rare diseases?